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Abstract
Introduction—Magnetic seizure therapy (MST), in which seizures are elicited with a high-
frequency magnetic field, is under development as a new treatment for major depressive disorder.
Its use may be justified if it produces the antidepressant effects of ECT, coupled with limited cognitive
side effects. This pilot study reports shortened recovery times after MST compared with ECT as a
preliminary step to evaluate the usefulness of a new 100Hz MST device.
Methods—We induced seizures with 100Hz magnetic transcranial stimulation in eleven patients
with major depressive disorder during one session of a regular course of ECT. Recovery times after
these MST and ECT induced seizures were compared.
Results—Seizures could be elicited in ten of the eleven patients. Stimulation over the vertex
produced tonic-clonic activity on nine out of eleven occasions. Stimulation over the prefrontal
midpoint elicited seizures on three out of seven occasions. The mean duration of magnetically
induced seizures was 31.3 sec, ranging from 10-86 sec. All patients had an exceptionally quick
recovery of orientation: mean of 7 min 12 sec (SD = 2 min 7 sec, range 4 min 20 sec – 9 min 41 sec).
The recovery times were on average 15 min 35 sec shorter with MST than with ECT in the same
patients (paired-samples t-test: p = 0.00009). Patients reported feeling less confused after MST. Side
effects were confined to myoclonic movements, associated with the use of etomidate.
Conclusions—The new 100 Hz magnetic stimulator elicits seizures in the majority of patients
when administered over the vertex. MST was associated with shorter recovery times and less
confusion following treatment. Subsequent work will be required to assess the safety and
effectiveness of MST in the treatment of depression.
*Corresponding author: Prof Klaus P Ebmeier, University of Oxford, Section of Old Age Psychiatry, Warneford Hospital, Oxford OX3
7JX.
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Introduction
Electroconvulsive therapy (ECT) is the most effective treatment for major depressive disorder
(1,2). However, its use is restricted, mostly due to concerns about cognitive side effects (3).
Modifications to the treatment procedure that could reduce the cognitive side effect burden are
therefore of great clinical interest. Since the introduction of repetitive transcranial magnetic
stimulation (rTMS), it was noticed that a rare side effect of this treatment was the induction of
seizures, when rTMS was used at high frequencies, high intensities, or with long train durations.
The possibility and safety of deliberately inducing seizures with repetitive magnetic fields was
first tested in nonhuman primates (4-8). The first human subject received a course of four
magnetic seizure therapy (MST) sessions in 2000, using 40 Hz at 100% intensity of the rTMS
equipment available at that time (9). A second patient was successfully treated with a full course
of MST with similar parameters (10). Both patients tolerated the treatments well and their
depressions responded. Following this, ten depressed patients received two MST sessions each
during a course of ECT, in a blinded, randomized within-subject cross-over trial. This time a
custom-modified device capable of producing 50 Hz stimulation at a peak magnetic field of
1.2 Tesla was used. Acute side effects of MST were milder compared with ECT (11,12).
Although seizures were induced in all patients, it was observed that in three patients the seizure
threshold was at the maximum output of the device, highlighting the need for technological
improvements in the equipment. Twenty depressed patients were treated with a full course of
MST using the same 50 Hz MST device in 2003 (13). MST improved depression scores and
patients demonstrated remarkably rapid reorientation with few side effects, though
improvements were smaller than those seen in the simultaneously treated group of ECT patients
(14). However, the maximum stimulation of 400 pulses per session was estimated to be on
average only 1.3 times the magnetic seizure threshold, perhaps contributing to the suboptimal
antidepressant efficacy, similar to some modes of ECT which are highly sensitive to dosage
relative to seizure threshold (15). These early trials were a proof of principle that MST could
induce therapeutic seizures in a clinical setting, but they also indicated the need for improved
MST devices (as discussed in (16)). Since then, available MST technology has significantly
advanced. A new prototype MST device (Magstim Company Limited) capable of stimulating
continuously at 100 Hz at maximum stimulator output (1.2 Tesla at the coil surface) for up to
10 seconds became available for animal use in 2004. This device was used for the first time in
2004 in a study of rhesus monkeys (16). Since then, 275 MST sessions have been successfully
performed in 11 rhesus monkeys. Seizures have been induced in all sessions, and 100 Hz MST
still demonstrates fewer cognitive side effects in the monkey model than conventional
electroconvulsive shock (17). A version of the 100 Hz MST device designed specifically for
human use (called the Magstim Theta) became available in the middle of 2006. The current
study was designed as a pilot to examine the feasibility of MST at 100Hz in patients, its safety
and side effects, and MST recovery times compared with ECT.
Patients and Methods
Eleven patients diagnosed with treatment resistant major depressive episodes in the context of
either recurrent Major Depression, or Schizoaffective Disorders according to DSM-IV criteria,
who had been referred for ECT, were enrolled in this pilot study. Demographic details are
presented in Table 1. Patients were treated in Whitchurch Hospital, Cardiff, and the Royal
Edinburgh Hospital. Eight of the patients were already receiving ECT, and one of their regular
(twice weekly sessions) was substituted with MST. The remaining three patients received MST
before ECT; two of these continued with ECT, the third decided against it. Local Research
Ethics Committee approval was obtained at both centres and patients gave written informed
consent following the approved protocols. In accordance with usual clinical practice of ECT
delivery in the UK, antidepressant medication was not stopped during the treatment. Every
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patient received at least one antidepressant, six were also taking one or more antipsychotics,
and two patients (patients 5 and 10 in the table) were also taking sodium valproate.
Magnetic Seizure Therapy
We used two custom-built Magstim Theta devices (Magstim Ltd, Whitland, Wales). This
stimulator is capable of producing 100 Hz magnetic stimuli at 1.2 Tesla (at the centre of the
coil) with a biphasic waveform with a pulse width of 340-400μs for up to 10 sec duration (i.e.
a maximum of 1000 pulses). We used a round coil with an 80 mm average diameter (47 mm
inside diameter, 115 mm outside diameter). For positioning of the coil we used standard 10-20
EEG positions. The middle of the coil was applied firmly to the head of the patients, and
positioned over Cz for vertical, and Fz for frontal stimulation for up to 10 seconds. The direction
of current induced in the brain was counter-clockwise. The inside of coils heats from 20 C° to
130 C° after 1000 pulses at 100% output stimulation; therefore coils were cooled down to 5-10
°C in a refrigerator prior to stimulation and were changed if a patient required re-stimulation.
All treatments were given at 100 Hz frequency and at maximum stimulator output. When a
patient was re-stimulated, we allowed at least 20 seconds between stimulations. Staff and
patients wore ear protectors during MST.
Anaesthesia
For anaesthesia we used intravenous (i.v.) etomidate (0.15 to 0.3 mg / kg) as it does not cause
an increase in the seizure threshold and might even reduce it, reviewed in (18). Muscle
relaxation was achieved with i.v. succinylcholine generally at a lower dose than that routinely
used in ECT (0.5 to 1.0 mg/kg), as recommended for MST due to the faster recovery of patients
(14).
Seizure monitoring
Seizure duration during MST was measured from the start of MST stimulation to the
termination of the observed seizure, cf. (12). EEG seizure expression was monitored via
bilateral fronto-mastoid EEG using MRI-compatible plastic electrodes to prevent electrode
heating during MST.
Orientation Assessment
Recovery of orientation after MST/ECT was assessed by asking the patient for their name, date
of birth, age, place, and day of the week. The point of orientation recovery was defined as the
time when a patient was able to recall four of these five items.
Results
The first treatment session with the new device took place in Cardiff in June 2006. The patient
was a 35 year old female, who had already received 5 bi-temporal ECT treatments, administered
at 195.8 mC. For MST, the coil was positioned over the vertex (Cz). Stimulation with 250
pulses produced no seizure. She was re-stimulated 52 sec later with 500 pulses and had a visible
motor seizure of 25 sec, EEG duration was approximately 21sec, but the endpoint was difficult
to estimate as there was no post-ictal suppression (EEG trace available from the authors on
request).
Orientation was recovered after 4 minutes 36 seconds. Immediately upon awakening, the
patient achieved a Mini Mental State Examination score of 27/30 points. On the next day, the
patient's score was at the pre-ECT level of 30 points. A battery of further cognitive tests that
included tests for verbal and visual memory, verbal fluency and executive speed was also
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administered and no relevant changes in performance from baseline were found (results not
presented).
We have since treated ten further patients. In order to explore optimal parameters of stimulation
for this new procedure, we applied different numbers of pulses and changed the positioning of
the coil between Cz and Fz. The results for each patient and the corresponding settings for their
ECTs are presented in Table 1.
Seizures were elicited in ten of the 11 patients. The one who did not fit was stimulated with
only 600 pulses. Vertex stimulation appeared to be more effective in inducing seizure activity
(Table 1; see patients number 3, 4, 6 and 8). The mean duration of successful seizures was 31.3
sec, range 9.5-86 sec.
Orientation was recovered much faster after MST than after ECT. The mean time to recovery
after successful seizures was 7 min 12 sec (SD = 2 min 7 sec, range 4 min 20 sec-9 min 41
sec). We compared these results with the recovery times of the same patients during their
nearest ECT session(s) taking care that the order of ECT and MST sessions used for the
calculation was approximately balanced. The mean recovery time after ECT was 26min 35sec.
When the recovery times of the nine patients who had both ECT and MST were compared in
a paired-samples t-test, MST was shown to result in 15 min 35 sec quicker recovery, and despite
the small numbers, this result was highly significant at p = 0.00009.
Patients uniformly commented that they felt less confused after MST. Side effects of 100 Hz
MST were restricted to the usual myotonic movements observed after etomidate anaesthesia.
No serious immediate adverse events resulted from the use of MST.
Discussion
We report the first use of a new MST device capable of sustaining maximum stimulator output
for 10 seconds at 100 Hz (1000 pulses). We treated 11 patients with a total of 18 stimulations.
To explore the range of seizure thresholds, we used a different number of pulses and two
positions of the coil: over vertex (Cz) or pre-frontally (Fz). Seizures were elicited in 10 of the
11 patients. The one who did not fit received only 600 pulses over the vertex. This was a 70-
year old woman who was on valproate, both age and anticonvulsant medication could account
for the difficulty to elicit a seizure. Eight more patients received stimulation over the vertex of
between 250 and 1000 pulses. One of these patients (our first patient) did not have a seizure
when we used 250 pulses, but she fitted when re-stimulated at 500 pulses. These findings
correspond to the previous observations that the mean seizure threshold with 50Hz MST was
at 268 (12) or 320 pulses (14).
We also tested if stimulation at 100 Hz was capable of inducing seizures over the pre-frontal
cortex, which had been difficult to achieve at lower frequencies (9,12,13). We attempted seven
prefrontal cortex stimulations in six patients. Of those, three were successful (one at 500 and
two at 1000 pulses) and four were not successful (one at 500, one at 600, and two at 1000
pulses). Patients who did not fit with prefrontal stimulation, fitted when stimulated over vertex
(Table 1). We conclude that even at the maximum setting of the machine, some patients will
only fit if the coil is positioned over the vertex (i.e. closest to the motor cortex, which has a
lower seizure threshold than pre-frontal or pre-central cortex).
We measured seizure duration during MST starting from the onset of stimulation. This is
because we observed that the seizures in MST start during the stimulation train. In contrast,
the convulsion typically does not start during electrical stimulation in ECT and a latent phase
is usually seen immediately after stimulation (19).
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The mean duration of successful MST seizures was 31.3 sec, range 10-86 sec. Four patients
had short seizures of 10, 18, 15 and 11sec (Table 1), which would not be considered therapeutic
if evoked by ECT. Two of these patients were stimulated with only 600 pulses, raising the
possibility that they may have had adequate seizures if stimulated at the maximum duration
output (10 sec) of the device.
In line with previous results (12), the recovery of orientation after MST was much faster than
after ECT. Despite the small sample size, this difference was highly statistically significant,
and more importantly, clinically meaningful. The ability to combine antidepressant efficacy
with low neuro-cognitive adverse effects would be invaluable for patients who require neuro-
stimulation therapies (20). All patients felt less confused after MST. Many patients felt as if
they had received no treatment and remembered details of what had happened immediately
prior to MST. For instance, patients were able to continue conversations after recovery that
had begun just prior to MST.
It has been noted that the EEG after MST differs markedly from that of ECT, with a lower
amplitude and relative absence of post-ictal suppression (12,14). We confirmed these
differences after stimulation at 100Hz. EEG traces during ECT showed high amplitude,
synchronised EEG activity and clear post-ictal suppression which were markedly different
from the EEG recorded after MST (traces available on request from the authors). The observed
differences between ECT and MST ictal expression on EEG could be due to the more focal
stimulation achieved with MST, which spares deeper brain regions such as the hippocampus
that may be implicated in the cognitive side effects of ECT (6). Differences in patterns of
seizure expression might also explain the much faster recovery after MST. Another explanation
for differences in ictal EEG expression between MST and ECT may stem from the fact that
we were not recording EEG from directly under the MST coil, where the induced currents and
seizure expression should be at its strongest. Specifically, our scalp EEG recordings were
collected from bilateral prefrontal cortex, while the most effective MST coil placement was
over the vertex. We have since observed that placing the electrodes over the motor cortex
during MST produces clearer seizure activity confirming our impression that these seizures
are more localised (Lisanby, personal communication).
Limitations of this work include the small sample size, open design, and non-randomized
nature. Nevertheless, this initial pilot study found that MST delivered with the new Magstim
Theta device was well tolerated and reliably produced seizures in the majority of patients, while
resulting in much less post-ictal confusion. These encouraging initial results beg the question
of the efficacy of this new investigational intervention for severe major depression. Previous
open studies using 40 Hz and 50 Hz MST (4,14) showed promising results, although MST did
not reach the effect size of optimal ECT. The ability to provide higher dosage MST seizures
relative to seizure threshold may narrow the gap in efficacy. This will be tested in the context
of new trials now underway using the 100 Hz device to assess the effectiveness and safety of
high dose MST relative to ECT.
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